Chloride ion
- Generic Name
- Chloride ion
- Drug Type
- Small Molecule
- Chemical Formula
- Cl
- CAS Number
- 16887-00-6
- Unique Ingredient Identifier
- Q32ZN48698
A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
Phase 2
Active, not recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- First Posted Date
- 2022-01-12
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- GrandPharma (China) Co., Ltd.
- Target Recruit Count
- 266
- Registration Number
- NCT05188417
- Locations
- 🇨🇳
23rd Floor, City Square, No.160 Qiaokou Road, Qiaokou District, Wuhan, Hubei, China
Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates
Early Phase 1
- Conditions
- Growth and DevelopmentNeonatal Necrotizing EnterocolitisPreterm InfantsNutrition
- Interventions
- Other: Autologous Umbilical Cord Blood Mononuclear Cells Therapy
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Guangdong Women and Children Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05138276
- Locations
- 🇨🇳
Jie Yang, Guangzhou, Guangdong, China
Effects of Continuous Dexmedetomidine Infusion on Systemic Microvascular Function in Laparoscopic Cholecystecthomy
Not Applicable
Recruiting
- Conditions
- Laparoscopic Surgery
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Institute of Cardiology, Laranjeiras, Brazil
- Target Recruit Count
- 70
- Registration Number
- NCT04946396
- Locations
- 🇧🇷
Eduardo Tibiriçá, Rio de Janeiro, Brazil
Phase 2 Study of RSLV-132 in Subjects With Long COVID
Phase 2
Completed
- Conditions
- Post-acute Corona Virus 19 (COVID-19) (Long COVID)
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 112
- Registration Number
- NCT04944121
- Locations
- 🇺🇸
Resolve Clinical Center, Seattle, Washington, United States
Immunomodulatory Effects of Dexmedetomidine Infusion
Not Applicable
- Conditions
- Major Abdominal Surgery
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 100
- Registration Number
- NCT04923737
- Locations
- 🇪🇬
Rehab Abd Elraof Abd Elaziz, Alexandria, Egypt
A First-in-Human Study to Assess the Safety and Tolerability of PDNO
Phase 1
Completed
- Conditions
- Pulmonary Hypertension
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- Attgeno AB
- Target Recruit Count
- 38
- Registration Number
- NCT04891354
- Locations
- 🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Sweden
A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension
Phase 1
Withdrawn
- Conditions
- Pulmonary HypertensionCOVID-19
- Interventions
- First Posted Date
- 2021-05-13
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Attgeno AB
- Registration Number
- NCT04885491
- Locations
- 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇸🇪Danderyd Hospital, Danderyd, Sweden
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT04878471
- Locations
- 🇯🇵
JP81001, Sumida-ku, Tokyo, Japan
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
Phase 3
Terminated
- Conditions
- COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
- Interventions
- Biological: C19-IG 20%
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 465
- Registration Number
- NCT04847141
- Locations
- 🇪🇸
Hospital Sant Pau i Santa Tecla, Tarragona, Spain
🇪🇸Centro de Salud San Andrés, Madrid, Spain
🇪🇸CAP Manso, Barcelona, Spain
Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.
Phase 4
Withdrawn
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- Drug: 2% Lidocaine HCl topical solution
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Milton S. Hershey Medical Center
- Registration Number
- NCT04810494
- Locations
- 🇺🇸
Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath